article thumbnail

Health insurer Excellus will not fund Alzheimer’s drug Aduhelm

pharmaphorum

Health insurer Excellus BlueCross BlueShield has said it will not cover treatment with Biogen and Eisai’s new Alzheimer’s disease drug Aduhelm because it has not been shown to be medically effective. The post Health insurer Excellus will not fund Alzheimer’s drug Aduhelm appeared first on.

article thumbnail

Navigating Pharmacy Insurance Coverage: How to Evaluate Insurance Plans for Your Business

Digital Pharmacist

One effective way to mitigate these risks is by having comprehensive insurance coverage. Determining the coverage needs and evaluating insurance requirements for your pharmacy can ensure you’re adequately protected in the face of any unforeseen circumstances.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Biogen admits slow Aduhelm launch, as scientists question label again

pharmaphorum

.” He blamed the poor performance on ” confusion, misinformation and controversy surrounding our data and the approval process.” “It is equally important to consider that the majority of patients with Alzheimer’s disease are likely to face higher risks of adverse events than the patients studied in the trials.”

article thumbnail

Frontiers Health Steering Committee spotlight: Eugene Borukhovich

pharmaphorum

In this latest coverage, pharmaphorum speaks with Eugene Borukhovich. Borukhovich is hesitant to compare this year’s conference with the 2021 event. “I These events are great on stage, but also in understanding what’s coming next.”. What ignites his interest is the drive of the individuals to show up at the event.

article thumbnail

NHC’s comments in response to the 2025 Notice of Benefit and Payment Parameters (NBPP)

Putting Patients First Blog

Making available more specific information about total costs and coverage will ensure that all consumers have comprehensive information to help them make smart health care decisions. These resources should aim to clarify insurance terms and concepts, aiding consumers in navigating the complexities of selecting a health plan.

article thumbnail

External control arms and debunking real-world data myths

pharmaphorum

In constructing an ECA, there are additional processes involved, such as planning the best study design, selecting the highest-quality clinical RWD source, defining the most appropriate inclusion/exclusion criteria, and conducting all necessary analyses to ensure the synthetic cohort is well matched to the experimental cohort. .

article thumbnail

NHC Comments on Medicare Drug Price Negotiation Program: Draft Guidance, Implementation of Sections 1191 – 1198 of the Social Security Act for Initial Price Applicability Year 2027 and Manufacturer Effectuation of the Maximum Fair Price (MFP) in 2026 and 2027

Putting Patients First Blog

We believe that patient-centric engagement is essential to ensure that the negotiation process leads to outcomes that genuinely benefit patients. Patient Engagement The NHC recognizes and commends CMS’ willingness to improve the listening sessions and the data submission processes. Improving the Data Collection (ICR) Process.